Adopting metaverse‐related mixed reality technologies to tackle urban development challenges: An empirical study of an Australian municipal government
IET Smart Cities · 2023-03 · 5 (1) · 64-72
DOI: 10.1049/smc2.12051 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Smart Cities, online erschienen am 14.02.2023. Verfasst von Aaron An. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Fast‐growing urban areas bring challenges to government authorities. The urban planning system in Australia is still very analogue with paper‐based systems as standard practice. Two‐dimensional document‐based blueprints and Geographic Information System (GIS) maps do not always give stakeholders and investors the necessary insights. By exploring Mixed Reality (MR) application at the municipal government level, this research explains how metaverse‐related immersive technologies can assist the government in better engaging with stakeholders and potential partners to improve their understanding of the urban environment and showcase future city developments to foster new opportunities and contribute to the development of the real living world.
Zitieren
APA
An, A. (2023). Adopting metaverse‐related mixed reality technologies to tackle urban development challenges: An empirical study of an Australian municipal government. IET Smart Cities, 5(1), 64-72. https://doi.org/10.1049/smc2.12051
Vancouver
An A. Adopting metaverse‐related mixed reality technologies to tackle urban development challenges: An empirical study of an Australian municipal government. IET Smart Cities. 2023;5(1):64-72. doi:10.1049/smc2.12051
BibTeX
@article{An2023,
author = {An, Aaron},
title = {Adopting metaverse‐related mixed reality technologies to tackle urban development challenges: An empirical study of an Australian municipal government},
journal = {IET Smart Cities},
year = {2023},
volume = {5},
number = {1},
pages = {64--72},
doi = {10.1049/smc2.12051}
}
EUVIMED